CMS' Changes to Reimbursement for Biosimilars

Amanda Forys, MSPH and Christy M. Gamble JD, DrPH, MPH, discuss CMS’ recent changes to reimbursement for biosimilars, and the impacts that these changes will have on patients under Medicare Part B and Part D.
February 20, 2018
View Text Version
x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.